Panacea Biotech is trading lower by 3.2% at Rs 175 after the World Health Organisation (WHO) delisted its DTP-based combination and monovalent hepatitis B vaccines from its list of pre-qualified vaccines.
The company, in a filing to the BSE, said that its diphtheria-pertussis-tetanus based combination vaccine Easyfive, Ecovac4 and EnivacHB have been delisted by WHO from the list of pre-qualified drugs. However, WHO stated there is no evidence of quality or safety defects regarding these vaccines.
The stock opened at Rs 176 and touched a high of Rs 183 in intra-day deals. As many as 15,800 shares have changed hands till 1050 hours.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app